Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, announced a strategic collaboration with an undisclosed biopharmaceutical company to integrate the IRO platform into a commercial cell therapy manufacturing process in a deal valued at up to $120M in services, milestones, equipment and consumable purchases over the next 10 years. The collaboration is designed to modernize the partner’s autologous cell therapy manufacturing infrastructure with the aim of expanding patient access to current and future potentially transformative cell therapies.
Through this collaboration, the parties will work together to demonstrate comparability of the IRO process to the existing commercial manufacturing process. The aim is to build a flexible and scalable manufacturing infrastructure that can support ongoing commercial supply as well as future development and commercialization needs. With 23 partners since launch in 2024, IRO is rapidly being adopted as the new standard in cell therapy manufacturing, reaching a new milestone in May 2026 with the dosing of the first patient treated with a therapy manufactured on the IRO platform and released under GMP.
This collaboration reflects a shared conviction by both partners that the future of autologous cell therapy depends not only on clinical benefits but also on the manufacturing infrastructure to deliver those benefits reliably and at scale to the patients who need them. With the signing of this partnership, both parties are firmly committed to pushing this objective forward together.
